NEVIS BRANDS INC - PSCBF STOCK NEWS

Pascal Biosciences (OTCPink:PSCBF) has announced a non-brokered private placement aiming to raise up to $900,000 by issuing 9 million units at $0.10 each. Each unit includes one share and one warrant, exerciseable at $0.15 for 24 months. The funds will be utilized for the development of PAS-403 and PAS-393 cancer therapies and for general working capital. The company recently received a $321,406 R21 grant from the National Cancer Institute for leukemia research. Rob Gietl has been appointed as the new CEO, succeeding Dr. Patrick Gray, who now serves as Chairman.

Pascal Biosciences has received a US$343,750 grant from the National Cancer Institute to develop its antibody drug for Acute Lymphoblastic Leukemia (ALL). This two-year grant aims to enhance treatment for over 6,000 patients diagnosed annually in North America, particularly affecting children. The drug may qualify for orphan drug designation, offering financial incentives and potential market exclusivity. Pascal has also filed for patent protection for this treatment. The company recently appointed Mark van der Horst as President, adding experience in capital markets.

Pascal Biosciences Inc. (OTC:PSCBF) appointed Rob Gietl as the new CEO and President. He brings extensive leadership experience and successfully managed $123M in financing at MYM Neutraceuticals. Gietl aims to leverage corporate partnerships and funding to advance Pascal's therapeutic programs, including PAS-393 and an NIH grant for leukemia. The transition sees Dr. Patrick Gray becoming Chairman of the Board.

Pascal Biosciences Inc. (OTC PINK: PSCBF) announced the appointment of Hardy Forzley as Chief Financial Officer, bringing 30 years of expertise in capital raising and corporate oversight. Forzley, formerly with Bathurst Metals Corp., is expected to enhance operational stewardship and shareholder value. Pascal is focused on innovative therapies for serious diseases, including cannabinoid treatments for cancer and a targeted therapy for acute lymphoblastic leukemia. The company is progressing with PAS-403 for glioblastoma and PAS-393 for various cancers and COVID-19.

Pascal Biosciences (OTC PINK: PSCBF) has received a $343,750 grant from the US National Cancer Institute to develop its antibody drug for Acute Lymphoblastic Leukemia (ALL), the most common childhood leukemia. This two-year funding will help advance their unique antibody targeting the VpreB protein, crucial for treating ALL. Each year, over 6,000 patients are diagnosed with ALL in Canada and the US. The drug is set to enter clinical trials and may qualify for orphan drug designation, enhancing its market potential.

Pascal Biosciences Inc. has received a new OTC trading symbol PSCBF following the acceptance of Form 211 by FINRA. This change aims to better reflect the company name. Mark van der Horst has been appointed as President, bringing over 30 years of capital markets experience. The company is focusing on enhancing corporate communications in Canada and the US. Pascal is a biotechnology firm developing therapies for serious diseases, including cancer and COVID-19. Their product pipeline includes PAS-403 for glioblastoma and PAS-393 for immuno-stimulatory treatments.